UK Markets open in 3 hrs 33 mins

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
20.000.00 (0.00%)
At close: 3:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.00
Open20.00
Bid0.00 x 0
Ask0.00 x 0
Day's range20.00 - 20.00
52-week range12.79 - 23.45
Volume518
Avg. volume58
Market cap586.054M
Beta (5Y monthly)0.66
PE ratio (TTM)15.60
EPS (TTM)1.28
Earnings dateN/A
Forward dividend & yield0.24 (1.14%)
Ex-dividend date21 Jun 2021
1y target estN/A
  • Globe Newswire

    IBA and RaySearch expand their partnership in proton therapy

    RaySearch Laboratories AB (publ) and IBA announce that they expanded their partnership in proton therapy within the areas of flash radiotherapy, proton ARC therapy, and treatment of moving tumors. Louvain-La-Neuve, Belgium, 26 October 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces RaySearch Laboratories AB (publ) and IBA expand their partnership in proton therapy within the areas of flash radiotherapy, proton ARC therapy, a

  • Globe Newswire

    IBA and the University of Pennsylvania partner to advance research of ConformalFLASH® therapy

    Multi-year research agreement to develop, test and validate ConformalFLASH® at the Roberts Proton Therapy Center Louvain-La-Neuve, Belgium, 25 October 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed an agreement with the University of Pennsylvania (Penn) to advance research in ConformalFLASH®1, a novel method combining ultra-high dose rate FLASH radiotherapy and the unique Bragg Peak properties of protons.

  • Globe Newswire

    Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida

    Louvain-La-Neuve, Belgium, October 24, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its proton therapy contract with Advocate Radiation Oncology, via its affiliate Southwest Florida Proton, has been finalized. IBA will start to recognize revenue from the contract in 2021. The finalization of the contract follows the announcement